Schwab Charles Investment Management Inc. raised its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 14.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 525,612 shares of the biopharmaceutical company’s stock after purchasing an additional 68,271 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Achillion Pharmaceuticals were worth $2,360,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Senzar Asset Management LLC acquired a new position in Achillion Pharmaceuticals in the second quarter valued at about $4,966,000. Candriam Luxembourg S.C.A. acquired a new position in Achillion Pharmaceuticals in the third quarter valued at about $1,976,000. Dimensional Fund Advisors LP boosted its position in Achillion Pharmaceuticals by 204.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,868,968 shares of the biopharmaceutical company’s stock valued at $8,579,000 after buying an additional 1,255,962 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Achillion Pharmaceuticals by 11.4% in the second quarter. Bank of New York Mellon Corp now owns 611,634 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 62,515 shares in the last quarter. Finally, Shell Asset Management Co. acquired a new position in Achillion Pharmaceuticals in the third quarter valued at about $902,000. Hedge funds and other institutional investors own 76.92% of the company’s stock.

Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at $2.90 on Thursday. Achillion Pharmaceuticals, Inc. has a 12-month low of $2.69 and a 12-month high of $5.66. The stock has a market cap of $399.79, a P/E ratio of -5.92 and a beta of 1.52.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04. During the same quarter last year, the business earned ($0.15) EPS. equities research analysts expect that Achillion Pharmaceuticals, Inc. will post -0.61 EPS for the current fiscal year.

ACHN has been the topic of a number of recent analyst reports. Leerink Swann restated a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Finally, Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $5.13.

In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.24% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/achillion-pharmaceuticals-inc-achn-holdings-boosted-by-schwab-charles-investment-management-inc/1812106.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.